Image pharmaphorum Editor News J&J files esketamine nasal spray antidepressant in US Drug targets 30% of people who don't respond to approved treatments News UK biotech Azeria pioneers research into cancer target FOXA1 A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for drug-resistant breast and prostate cancer, based around a new target known as FOXA1. News Vyasa links with NVIDIA to boost AI capability Artificial Intelligence (AI) healthcare firm Vyasa Analytics has joined a programme designed to nurture start-ups using cutting-edge technology. News Pfizer drug reduces mortality in patients with fatal heart d... Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial. Load more results
News J&J files esketamine nasal spray antidepressant in US Drug targets 30% of people who don't respond to approved treatments
News UK biotech Azeria pioneers research into cancer target FOXA1 A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for drug-resistant breast and prostate cancer, based around a new target known as FOXA1.
News Vyasa links with NVIDIA to boost AI capability Artificial Intelligence (AI) healthcare firm Vyasa Analytics has joined a programme designed to nurture start-ups using cutting-edge technology.
News Pfizer drug reduces mortality in patients with fatal heart d... Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
